Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Mumps

Part of Human Metapneumovirus Infection

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Mumps

26 trials tracked for Mumps: 22 in phase 3 or 4 and 9 with published results. The most-cited published study has 38 citations.

26Trials tracked

22Phase 3 & 4

0Recruiting

9With published results

Phase distribution

Phase 4 2 Phase 3 20 Phase 2 4

Phase 3 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed · 38 cited
Phase 3 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed · 30 cited
Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed · 20 cited
Phase 3 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed · 19 cited
Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed · 14 cited
Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited

Show 20 more trials

Phase 3 ProQuad® Intramuscular vs Subcutaneous Completed · 10 cited
Phase 3 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed · 10 cited
Phase 3 Safety Study of ProQuad® rHA in Infants (V221-037) Completed · 9 cited
Phase 4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Completed
Phase 4 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed
Phase 3 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed
Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
Phase 3 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed
Phase 3 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed
Phase 3 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed
Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed
Phase 3 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed
Phase 3 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed
Phase 3 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed
Phase 2 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed
Phase 2 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed
Phase 2 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed
Phase 2 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Mumps: what the trials found

Several phase 3 trials demonstrate high seropositivity rates for mumps following vaccination with various MMR-containing vaccines. For instance, Priorix showed anti-mumps antibody concentrations above the cut-off in 98.0-99.7% of subjects across multiple studies ⁵⁷. Similarly, ProQuad achieved mumps seropositivity rates of 96.3-99.5% after dose 2 ⁴⁸⁹. A phase 4 trial of the SA 14-14-2 Japanese Encephalitis vaccine reported mumps seropositivity of 98.5% ¹.

Concomitant administration of MMR with other vaccines (e.g., Japanese encephalitis chimeric virus vaccine) did not impair mumps seroconversion, with rates of 96.9-100% ¹³. However, one trial comparing MMRV to MMR+V found lower mumps antibody levels (≥10 Units/mL) in the MMRV group (97.2% vs 98.2%, p<0.001) ¹⁴, indicating mixed evidence for combined vaccines.

Safety profiles were generally acceptable. Solicited injection-site adverse reactions after ProQuad dose 2 occurred in 10.4-17.2% of participants ⁴. In a Priorix trial, any solicited local symptoms were reported in 15-26 subjects per group ¹². Fever was common after MMRV vaccination (76/450 subjects) ⁶.

For the clinician treating this condition

MMR-containing vaccines (Priorix, ProQuad) consistently induce high mumps seropositivity rates (≥96%) in children.
Concomitant administration with other vaccines does not compromise mumps immune response.
Mild injection-site reactions and fever are common but generally well-tolerated.

AI synthesis of 10 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.